Monthly Archives: May 2009

India turns hub of clinical research outsourcing

May 26th, 2009|

India is fast turning into a global hub of cost-effective clinical research outsourcing (CRO), thanks to the adaptation of international regulatory standards. The revenue from this sector is expected to touch $1 billion by 2010. From $70 million pumped in by just a few pharmaceutical companies to India in 2002, the revenue from clinical research outsourcing has leaped to $800 million now, according to industry insiders

Drug-resistant bacteria mute antibiotics R&D

May 26th, 2009|

Overprescription and indiscriminate use of a particular class of drugs is leading to the problem of micro-organisms developing resistance to medicines. This is creating major roadblocks in bringing novel molecules to the market.

Heard on the Street

May 26th, 2009|

QIP-bound cos seen making most of Bull RunThe recent improvement in market sentiment has triggered a flurry of Quality Improvement Programme (QIPs) by Companies of late. Optimists have interpreted the fund-raising activity by companies as a sign that the bullish times are back. But a section of the investors refuse to buy this argument.

Gujarat-based pharma firms in pink of health

May 26th, 2009|

In the time of economic slowdown when major companies are facing pressure on their balance sheets, Gujarat-based pharmaceutical firm have registered a healthy growth and seen substantial rise in net profit in the financial year 2008-09.

Indian Pharmaceutical Industry Capable of Dealing with Any Situation

May 26th, 2009|

The recent outbreak of HINI Influenza A virus (swine flu) in different parts of the world has provided an opportunity to Indian pharmaceutical industry to demonstrate its strength in terms of its ability to alter manufacturing ability in short period.

India now a player in M & A premier league

May 26th, 2009|

India will enter the global pecking order of the largest M&A's done so far this year with the proposed Bharti Airtel-MTNL deal. It will be the third largest deal so far in 2009 and if pharma is excluded, it will be the largest deal so far globally.

Dabur plans big expansion in skin care, to launch new brand

May 26th, 2009|

FMCG major Dabur is stepping up expansion in the skin care segment, on the back of its acquisition of Fem Care Pharma last year; with plans to expand range of products from the latter's stable besides launching a new brand of its own.

Investors at risk as US FDA gets tough with drug cos

May 26th, 2009|

The recent warning letters issued by the US Food and Drug Administration (FDA), to manufacturing units of Indian pharmaceutical  companies, have significantly raised investors risk.

Pharmexcil to setup expert cell to advise pharma SMEs in export, patent issues

May 26th, 2009|

The Pharmaceutical Exports Promotion Council (Pharmexcil) will soon appoint an expert advisory cell under its aegis to support the pharma small and medium entrepreneurs (SMEs) entering into new overseas markets.

Pharmaceutical a Big Business

May 26th, 2009|

The Malaysian pharmaceutical market is a serious business, with significant growth in the last decade at between 8% and 10% annually.

Akela Pharma to buy Nventa Biopharma in stock deal of 1.4 mn Dollars

May 26th, 2009|

Akela Pharma and Nventa Biopharmaceuticals executed an arrangement agreement to combine the two companies by way of a plan of arrangement under the Business Corporations Act (British Columbia). The board of directors of both companies unanimously approved the agreement.

Midmarket pharmaceutical deals could heat up

May 26th, 2009|

Middle-market M&A in the pharmaceutical sector has been at a steady, lukewarm pace, but four deals in May, according to a report, could be a sign that midrange M&A activity may heat up in the coming months.

Over 44 fixed-dose combination drugs clear DGCI tests

May 24th, 2009|

The government may give permission to 44 more combination drugs a formulation of two or more active ingredients combined in certain fixed doses – for treating diarrhoea, fever, pain and hypertension, said a health ministry official.

Cardiome bags US 60 mn dollar from Merck as collaboration, license pact become effective

May 21st, 2009|

Cardiome Pharma Corp announced that the waiting period under the Hart-Scott-Rodino Act for the collaboration and license agreement with Merck & Co. Inc and a Merck affiliate for development and commercialisation of vernakalant, an investigational candidate for the treatment of atrial fibrillation, has expired and the agreement is now effective.

Indian pharma players to benefit from generic drugs in US

May 21st, 2009|

Increased use of generic drugs helped the US healthcare system save billions of dollars over the last decade.

Pharma Trials Heading South

May 21st, 2009|

Sanofi-Aventis’ recent acquisitions in Latin America are part of a growing trend of pharma companies looking to expand away from their traditional strongholds in the US and Europe.

Novartis nabs Ebewe for generics push

May 21st, 2009|

The word of the day: generics. While Pfizer was out making deals in India, Novartis was negotiating to buy Ebewe Pharma's cancer drugs unit–for a respectable $1.3 billion.

Pfizer nabs generics, emerging-market rights

May 21st, 2009|

Pfizer hasn't been standing idly by as its rivals forge ahead into generics and emerging markets.

Dept of Pharma designs e-commerce project to support SME pharma sector

May 21st, 2009|

The Department of Pharmaceuticals is exploring the possibility of bringing in an e-commerce project to strengthen the small and medium pharmaceutical enterprises.

Cancer drugs may come under NPPA lens

May 20th, 2009|

Cancer drugs may soon come under the purview of India’s drug price regulator, as they have become too expensive for the common man to afford, according to Drug Controller General of India (DCGI) Surinder Singh.